Annals of internal medicine Journal Impact Factor & Information

Publisher: American College of Physicians, American College of Physicians

Journal description

Established in 1927 by the American College of Physicians (ACP), the Annals of Internal Medicine is the leading journal for studies in internal medicine. The purpose of the journalñto promote excellence in the clinical practice of internal medicineñis supported by presentation of a wide variety of experimental and clinical subject matter in the Article, Brief Communication, Update, and Review formats. And to support the belief that physicians should also be well-informed citizens of both the medical community and society at large, Annals offers background and discussion of issues that influence both physicians and patients. This information is primarily carried in the Perspective, In the Balance, and Editorial formats. In addition, the journal presents personal narratives in the On Being a Doctor and the On Being a Patient formats that convey the feeling and the art of medicine.

Current impact factor: 16.10

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 16.104
2012 Impact Factor 13.976
2011 Impact Factor 16.733
2010 Impact Factor 16.729
2009 Impact Factor 16.225
2008 Impact Factor 17.457
2007 Impact Factor 15.516
2006 Impact Factor 14.78
2005 Impact Factor 13.254
2004 Impact Factor 13.114
2003 Impact Factor 12.427
2002 Impact Factor 11.414
2001 Impact Factor 11.13
2000 Impact Factor 9.833
1999 Impact Factor 10.097
1998 Impact Factor 10.9
1997 Impact Factor 12.047
1996 Impact Factor 11.21
1995 Impact Factor 9.92
1994 Impact Factor 9.887
1993 Impact Factor 9.297
1992 Impact Factor 10.217

Impact factor over time

Impact factor
Year

Additional details

5-year impact 16.26
Cited half-life 9.70
Immediacy index 4.01
Eigenfactor 0.11
Article influence 7.54
Website Annals of Internal Medicine website
Other titles Annals of internal medicine (Online), Annals of internal medicine, Annals.org
ISSN 1539-3704
OCLC 37354934
Material type Online system or service, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

American College of Physicians

  • Pre-print
    • Archiving status unclear
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 6 months embargo
  • Conditions
    • Authors may deposit in PubMed Central only
    • Publisher's version/PDF cannot be used
    • Set statement to accompany deposit (see policy)
    • Publisher last reviewed on 04/11/2014
  • Classification
    ​ white

Publications in this journal

  • Annals of internal medicine 05/2015;
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0273
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0274
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0242
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this best practice advice article is to describe the indications for screening for cervical cancer in asymptomatic, average-risk women aged 21 years or older. The evidence reviewed in this work is a distillation of relevant publications (including systematic reviews) used to support current guidelines. Clinicians should not screen average-risk women younger than 21 years for cervical cancer. Clinicians should start screening average-risk women for cervical cancer at age 21 years once every 3 years with cytology (cytologic tests without human papillomavirus [HPV] tests). Clinicians should not screen average-risk women for cervical cancer with cytology more often than once every 3 years. Clinicians may use a combination of cytology and HPV testing once every 5 years in average-risk women aged 30 years or older who prefer screening less often than every 3 years. Clinicians should not perform HPV testing in average-risk women younger than 30 years. Clinicians should stop screening average-risk women older than 65 years for cervical cancer if they have had 3 consecutive negative cytology results or 2 consecutive negative cytology plus HPV test results within 10 years, with the most recent test performed within 5 years. Clinicians should not screen average-risk women of any age for cervical cancer if they have had a hysterectomy with removal of the cervix.
    Annals of internal medicine 04/2015; DOI:10.7326/M14-2426
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0153
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0272
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0298
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0262
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0206
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0271
  • [Show abstract] [Hide abstract]
    ABSTRACT: Guidelines recommend statins as first-line therapy for dyslipidemia. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) are a new lipid-lowering approach. To assess the efficacy and safety of PCSK9 antibodies in adults with hypercholesterolemia. MEDLINE, PubMed Central, and Google Scholar; conference proceedings; and the ClinicalTrials.gov registry through 4 April 2015. Phase 2 or 3 randomized, controlled trials (RCTs) comparing treatment using PCSK9 antibodies with no anti-PCSK9 therapy in adults with hypercholesterolemia. Two investigators independently extracted data on study characteristics and lipid and clinical outcomes, and rated risk of bias of trials. Prespecified primary end points were all-cause and cardiovascular mortality. Twenty-four RCTs comprising 10 159 patients were included. Compared with no antibody, treatment with PCSK9 antibodies led to marked reductions in low-density lipoprotein cholesterol levels (mean difference, -47.49% [95% CI, -69.64% to -25.35%]; P < 0.001] and other atherogenic lipid fractions, and it reduced all-cause mortality (odds ratio [OR], 0.45 [CI, 0.23 to 0.86]; P = 0.015; heterogeneity P = 0.63; I2 = 0%) and cardiovascular mortality (OR, 0.50 [CI, 0.23 to 1.10]; P = 0.084; heterogeneity P = 0.78; I2 = 0%). The rate of myocardial infarction was significantly reduced with use of PCSK9 antibodies (OR, 0.49 [CI, 0.26 to 0.93]; P = 0.030; heterogeneity P = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 to 0.96]; P = 0.026; heterogeneity P = 0.65; I2 = 0%). Serious adverse events did not increase with administration of PCSK9 antibodies. Results were derived from study-level data rather than patient-level data, and clinical outcome data are rare. PCSK9 antibodies seem to be safe and effective for adults with dyslipidemia. CRC 1116 Masterswitches in Myocardial Ischemia, German Research Council DFG.
    Annals of internal medicine 04/2015; DOI:10.7326/M14-2957
  • Annals of internal medicine 04/2015; DOI:10.7326/M15-0920
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since 1990, progress has been made toward global tuberculosis (TB) control, as measured by targets set for 2015. However, TB remains a major threat to health around the world. In 2013, there were an estimated 11 million prevalent cases, and an estimated 9.0 million incident cases occurred globally. Approximately 1.5 million deaths were caused by TB, including 360 000 among people living with HIV. Substantial challenges threaten future control efforts. These include multidrug-resistant forms and co-infection with HIV, as well as other factors, such as the increased prominence of noncommunicable diseases and adverse socioeconomic conditions. Beyond 2015, TB control must be seen as both a public health imperative unto itself and a vital component of economic development plans. To that end, control strategies should exploit technical and operational innovations to improve TB control and care and should promote universal health coverage and social protection mechanisms to expand access to essential prevention, diagnostics, and treatment services while avoiding catastrophic costs incurred by patients.
    Annals of internal medicine 04/2015; DOI:10.7326/M14-2210
  • [Show abstract] [Hide abstract]
    ABSTRACT: Novel interferon- and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection. To evaluate the safety and efficacy of grazoprevir (NS3/4A protease inhibitor) and elbasvir (NS5A inhibitor) in treatment-naive patients. Randomized, blinded, placebo-controlled trial. (ClinicalTrials.gov: NCT02105467). 60 centers in the United States, Europe, Australia, Scandinavia, and Asia. Cirrhotic and noncirrhotic treatment-naive adults with genotype 1, 4, or 6 infection. Oral, once-daily, fixed-dose grazoprevir 100 mg/elbasvir 50 mg for 12 weeks, stratified by fibrosis and genotype. Patients were randomly assigned 3:1 to immediate or deferred therapy. Proportion of patients in immediate-treatment group achieving unquantifiable HCV RNA 12 weeks after treatment (SVR12); adverse events in both groups. Among 421 participants, 194 (46%) were women, 157 (37%) were nonwhite, 382 (91%) had genotype 1 infection, and 92 (22%) had cirrhosis. Of 316 patients receiving immediate treatment, 299 of 316 (95% [95% CI, 92% to 97%]) achieved SVR12, including 144 of 157 (92% [CI, 86% to 96%]) with genotype 1a, 129 of 131 (99% [CI, 95% to 100%]) with genotype 1b, 18 of 18 (100% [CI, 82% to 100%]) with genotype 4, 8 of 10 (80% [CI, 44% to 98%]) with genotype 6, 68 of 70 (97% [CI, 90% to 100%]) with cirrhosis, and 231 of 246 (94% [CI, 90% to 97%]) without cirrhosis. Virologic failure occurred in 13 patients (4%), including 1 case of breakthrough infection and 12 relapses, and was associated with baseline NS5A polymorphisms and emergent NS3 or NS5A variants or both. Serious adverse events occurred in 9 (2.8%) and 3 (2.9%) patients in the active and placebo groups, respectively (difference <0.05 percentage point [CI, -5.4 to 3.1 percentage points]); none were considered drug related. The most common adverse events in the active group were headache (17%), fatigue (16%), and nausea (9%). The study lacked an active-comparator control group and included relatively few genotype 4 and 6 infections. Grazoprevir-elbasvir achieved high SVR12 rates in treatment-naive cirrhotic and noncirrhotic patients with genotype 1, 4, or 6 infections. This once-daily, all-oral, fixed-combination regimen represents a potent new therapeutic option for chronic HCV infection. Merck & Co.
    Annals of internal medicine 04/2015; DOI:10.7326/M15-0785
  • Annals of internal medicine 04/2015; 162(8):596. DOI:10.7326/L15-5071
  • [Show abstract] [Hide abstract]
    ABSTRACT: In December 2013, the U.S. Preventive Services Task Force recommended screening for lung cancer with low-dose computed tomography (LDCT) for selected current and former smokers. The Task Force based the recommendation primarily on the results of the NLST (National Lung Screening Trial). In this trial, patients randomly assigned to LDCT screening for 3 years had lower rates of both lung cancer-specific mortality and all-cause mortality (relative risk reduction, 6.7% [95% CI, 1.2% to 13.6%]; absolute risk reduction, 0.46% [CI, 0% to 0.9%]). Clinicians and health systems confront questions and challenges as they begin to implement lung cancer screening. This paper summarizes a conference during which an internist and a radiologist discuss the application of the Task Force recommendation to an individual patient.
    Annals of internal medicine 04/2015; 162(8):577-582. DOI:10.7326/M15-0055
  • [Show abstract] [Hide abstract]
    ABSTRACT: One driver of increasing health care costs is the use of radiologic imaging procedures. More appropriate use could improve quality and reduce costs. To review interventions that use the computerized clinical decision-support (CCDS) capabilities of electronic health records to improve appropriate use of diagnostic radiologic test ordering. English-language articles in PubMed from 1995 to September 2014 and searches in Web of Science and PubMed of citations related to key articles. 23 studies, including 3 randomized trials, 7 time-series studies, and 13 pre-post studies that assessed the effect of CCDS on diagnostic radiologic test ordering in adults. 2 independent reviewers extracted data on functionality, study outcomes, and context and assessed the quality of included studies. Thirteen studies provided moderate-level evidence that CCDS improves appropriateness (effect size, -0.49 [95% CI, -0.71 to -0.26]) and reduces use (effect size, -0.13 [CI, -0.23 to -0.04]). Interventions with a "hard stop" that prevents a clinician from overriding the CCDS without outside consultation, as well as interventions in integrated care delivery systems, may be more effective. Harms have rarely been assessed but include decreased ordering of appropriate tests and physician dissatisfaction. Potential for publication bias, insufficient reporting of harms, and poor description of context and implementation. Computerized clinical decision support integrated with the electronic health record can improve appropriate use of diagnostic radiology by a moderate amount and decrease use by a small amount. Before widespread adoption can be recommended, more data are needed on potential harms. U.S. Department of Veterans Affairs. (PROSPERO registration number: CRD42014007469).
    Annals of internal medicine 04/2015; 162(8):557-565. DOI:10.7326/M14-2600
  • Annals of internal medicine 04/2015; 162(8):JC8. DOI:10.7326/ACPJC-2015-162-8-008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prediabetes affects 1 in 3 Americans. Both intensive lifestyle intervention and metformin can prevent or delay progression to diabetes. Over the past decade, lifestyle interventions have been translated across various settings, but little is known about the translation of evidence surrounding metformin use. To examine metformin prescription for diabetes prevention and patient characteristics that may affect metformin prescription. Retrospective cohort analysis over a 3-year period. Employer groups that purchased health plans from the nation's largest private insurer. A national sample of 17 352 working-age adults with prediabetes insured for 3 continuous years between 2010 and 2012. Percentage of health plan enrollees with prediabetes who were prescribed metformin. Only 3.7% of patients with prediabetes were prescribed metformin over the 3-year study window. After adjustment for age, income, and education, the predicted probability of metformin prescription was almost 2 times higher among women and obese patients and more than 1.5 times higher among patients with 2 or more comorbid conditions. Missing data on lifestyle interventions, possible misclassification of prediabetes and metformin use, and inability to define eligible patients exactly as defined in the American Diabetes Association guidelines. Evidence shows that metformin is rarely prescribed for diabetes prevention in working-age adults. Future studies are needed to understand potential barriers to wider adoption of this safe, tolerable, evidence-based, and cost-effective prediabetes therapy. Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive and Kidney Diseases.
    Annals of internal medicine 04/2015; 162(8):542-548. DOI:10.7326/M14-1773